Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| MedCapital | Healthcare Services | 30.4% | 90th pct | 268 |
| Silk Medikal | Healthcare Services | 16.3% | 69th pct | 268 |
| Medison Holding | Healthcare Services | 12.8% | 57th pct | 268 |
| Reimani | Healthcare Services | -12.8% | 12th pct | 268 |
| Adiktologiis Regionalur… | Healthcare Services | — | no FY data | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 4 of 5 peers filed FY2024. Switch to FY2023 (5 of 5).
| Ratio — FY 2024 | Reimani | Medison Holding | MedCapital | Silk Medikal | Adiktologiis Regionalur… |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 29.0% | 100.0% | 93.4% | 100.0% | — |
| EBITDA Margin | -12.8% | 12.8% | 30.4% | 16.3% | — |
| EBITDAR | -1,475 | 2,350 | 2,934 | 1,878 | — |
| EBITDAR Margin | -12.8% | 20.5% | 30.4% | 23.8% | — |
| EBIT Margin | -14.6% | 10.5% | 20.8% | 10.8% | — |
| Net Profit Margin | -15.1% | -1.9% | 21.4% | 10.8% | — |
| Operating Expense % of Sales | 41.8% | 87.2% | 63.0% | 83.7% | — |
| Returns | |||||
| Return on Assets (ROA) | -27.6% | -1.4% | 12.0% | 22.3% | — |
| Return on Equity (ROE) | N/A | -13.9% | 14.1% | 44.3% | — |
| ROIC [EBIT / Invested Capital] | |||||
| -49.4% |
| 8.5% |
| 13.7% |
| 52.0% |
| — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 173.5% | 81.9% | 0.0% | 34.5% | — |
| Debt-to-Equity | -1.50x | 8.27x | 0.00x | 0.69x | — |
| Debt-to-EBITDA | N/A | 8.78x | 0.00x | 1.03x | — |
| Equity-to-Assets | -116.0% | 9.9% | 85.2% | 50.3% | — |
| Net Debt | 10,712 | 12,620 | -24 | -283 | — |
| Cash & Equivalents | 222 | 313 | 24 | 1,603 | — |
| Total Debt | 10,934 | 12,933 | N/A | 1,320 | — |
| Liquidity & working capital | |||||
| Current Ratio | 0.90x | 0.70x | 0.49x | 6.57x | — |
| Quick Ratio | 0.90x | 0.70x | 0.45x | 6.57x | — |
| Cash Ratio | 0.07x | 0.14x | 0.01x | 2.75x | — |
| Total Current Assets | 2,915 | 1,593 | 1,252 | 3,827 | — |
| Total Current Liabilities | 3,240 | 2,278 | 2,544 | 582 | — |
| Inventory | N/A | N/A | 104 | N/A | — |
| Trade Receivables | 728 | 995 | 1,124 | 3 | — |
| Trade Payables | 1,196 | 844 | 2,544 | 575 | — |
| Net Working Capital | -324 | -685 | -1,292 | 3,244 | — |
| Net Working Capital % of Revenue | -2.8% | -6.0% | -13.4% | 41.1% | — |
| Trade Working Capital | -468 | 150 | -1,316 | -572 | — |
| Trade Working Capital % of Revenue | -4.1% | 1.3% | -13.7% | -7.3% | — |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | — |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | N/A | 6.12x | N/A | — |
| Days Inventory Outstanding (DIO) | N/A | N/A | 59.6 | N/A | — |
| Receivables Turnover | 15.82x | 11.54x | 8.58x | 2749.63x | — |
| Days Sales Outstanding (DSO) | 23.1 | 31.6 | 42.5 | 0.1 | — |
| Payables Turnover | 6.84x | N/A | 0.25x | N/A | — |
| Days Payable Outstanding (DPO) | 53.4 | N/A | 1464.6 | N/A | — |
| Cash Conversion Cycle | -30.3 days | 31.6 days | -1362.4 days | 0.1 days | — |
| Asset Turnover | 1.83x | 0.73x | 0.56x | 2.06x | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | 579 | N/A | 3,605 | N/A | — |
| Free Cash Flow (OCF − Capex proxy) | 87 | N/A | -306 | N/A | — |
| Cash Conversion (OCF / EBITDA) | N/A | N/A | 122.9% | N/A | — |
| Dividends Declared | N/A | N/A | 3,000 | N/A | — |
| Dividend Payout Ratio | N/A | N/A | 145.4% | N/A | — |